Selumetinib /m2

Phase 3Small molecule

NNational Cancer Institute (NCI)

Selumetinib /m2 is one of 257 small molecule programs targeting Glioma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

256

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Peritoneum CancerActive, not recruiting

NeurofibromatosisActive, not recruiting

Tic DisorderActive, not recruiting

Neurofibromatosis Type 1Active, not recruiting

Pancreatic CancerActive, not recruiting

Gastrointestinal Stromal TumorActive, not recruiting

Endometrial CancerActive, not recruiting

GliomaPhase 3

Active, not recruiting

Peritoneum CancerPhase 2

Active, not recruiting

NeurofibromatosisPhase 3

Active, not recruiting

Tic DisorderPhase 2

Active, not recruiting

Neurofibromatosis Type 1Phase 2

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Gastrointestinal Stromal TumorPhase 2

Active, not recruiting

Endometrial CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Selumetinib /m2

NNational Cancer Institute (NCI)

Phase 3

1 2

Gemzar

GGynecologic Oncology Group

Byetta

1 4

Medrol

Pfizer

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

ABI-007

Bristol-Myers Squibb

Preclinical

2 7

Active Comparator

Moderna

Preclinical

1 8

LDE225

Novartis

Preclinical

1 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

Thiazolidinediones

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Low Grade Astrocytoma

NCT04576117

Q1 2027

Phase 2Active, not recruiting

Tic Disorder

NCT03155620

Q4 2027

Phase 3Active, not recruiting

Low Grade Glioma

NCT03871257

Q4 2028

Phase 2Recruiting

Recurrent Endometrial Carcinoma

NCT05554328

Clinical

Trials by Indication[1]

Tic Disorder2 trials

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT03213691·21 enrolled

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03155620·1,376 enrolled

Pancreatic Cancer1 trial

Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT03040986·8 enrolled

Peritoneum Cancer1 trial

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00551070·52 enrolled

Neurofibromatosis Type 11 trial

Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02839720·11 enrolled

Solid Malignancies1 trial

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT01364051·19 enrolled

6 more indications

Glioma1 trial

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

Recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT04166409·170 enrolled

Gastrointestinal Stromal Tumor1 trial

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT03109301

Recurrent Endometrial Carcinoma1 trial

A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05554328·165 enrolled

Advanced Malignant Solid Neoplasm1 trial

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05564377·2,900 enrolled

Low Grade Astrocytoma1 trial

A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT04576117·300 enrolled

Low Grade Glioma1 trial

A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT03871257·165 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Selumetinib /m2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Selumetinib /m2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Selumetinib /m2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNational Cancer Institute (NCI)

Selumetinib /m2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q4 2027

Q4 2028

Trials by Indication[1]

Tic Disorder2 trials

Pancreatic Cancer1 trial

Peritoneum Cancer1 trial

Neurofibromatosis Type 11 trial

Solid Malignancies1 trial

Glioma1 trial

Gastrointestinal Stromal Tumor1 trial

Recurrent Endometrial Carcinoma1 trial

Advanced Malignant Solid Neoplasm1 trial

Low Grade Astrocytoma1 trial

Low Grade Glioma1 trial

References

Drug Info

Quick Facts

Related News